A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19
Status:
Recruiting
Trial end date:
2021-02-14
Target enrollment:
Participant gender:
Summary
This study aims to investigate the potential antiviral efficacy and safety of a novel
formulation of Niclosamide; a well-known antihelmintic agent, together with an established
COVID-19 treatment regimen in patients.
The aim of this study is to evaluate the safety and efficacy profile of niclosamide from the
test product (Niclosamide 200 mg/10 mL Suspension) in patients treated for the novel
coronavirus infectious disease (COVID-19) in a placebo controlled phase III trial. Both
treatment groups will receive an established treatment regimen against COVID-19 together with
either niclosamide or placebo.
The efficacy and safety of the molecule is well-known and the properties of novel formulation
is well-established. The promising in vitro results of niclosamide as an antiviral compound
is well documented and make it an ideal candidate as a therapy against SARS-CoV 2 infection.
A good safety profile is expected with solid antiviral activity.